3 Key Takeaways
Plain English Summary- 01Core Finding
Dupilumab versus placebo (inactive comparison treatment) achieved >100 mL improvements in pre-bronchodilator FEV1 at week 12 (42.2% vs 31.1%) and week 52 (36.9% vs 31.2%), with a similar proportion for post-bronchodilator FEV1 at weeks 12 and 52.
- 02Study Evidence
Tested in a randomized controlled trial (n = 938) at the randomized clinical trial stage.
- 03Practical Meaning
Controlled trial findings show causal benefit under protocol rules; real-world effectiveness can vary across patients.
What This Means for You
Dupilumab treatment resulted in early and sustained improvements across multiple spirometric lung function parameters in patients with COPD and type 2 inflammation.
The Discovery
To perform in-depth analyses of the efficacy (real-world effectiveness in the trial) of dupilumab on lung function parameters in patients with COPD and type 2 inflammation. In BOREAS (NCT03930732) and NOTUS (NCT04456673), patients with COPD and type 2 inflammation were randomized to dupilumab 300 mg (n = 938) or placebo (n = 936) subcutaneously every 2 weeks for 52 weeks. Dupilumab versus placebo (inactive comparison treatment) improved pre-bronchodilator forced expiratory volume in 1 second (FEV1; least squares mean difference: 83 [a clinically meaningful level confidence interval (CI): 53-112] mL; P <.0001), post-bronchodilator FEV1 (71 [41-101] mL; P <.0001), pre-bronchodilator forced vital capacity (FVC; 64 [26-102] mL; P =.0009), post-bronchodilator FVC (41 [3-79] mL; P =.0341), post-bronchodilator FEV1/FVC (0.016 [0.010-0.022]; P <.0001), and forced expiratory flow a clinically meaningful level-a clinically meaningful level of FVC (78 [45-111] mL/s; P <.0001) at week 12 and sustained to week 52. Improvements in pre-bronchodilator FEV1 were observed regardless of smoking status or the presence of co-existing emphysema; greater improvements were observed in patients with higher baseline eosinophil counts or fractional exhaled nitric oxide. Dupilumab versus placebo achieved >100 mL improvements in pre-bronchodilator FEV1 at week 12 (a clinically meaningful level vs a clinically meaningful level) and week 52 (a clinically meaningful level vs a clinically meaningful level), with a similar proportion for post-bronchodilator FEV1 at weeks 12 and 52.
How It Works, Simply
This pulmonology research focuses on inflammation. Researchers evaluated it using a randomized controlled trial (n = 938) at the randomized clinical trial stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
Dupilumab versus placebo achieved >100 mL improvements in pre-bronchodilator FEV1 at week 12 (42.2% vs 31.1%) and week 52 (36.9% vs 31.2%), with a similar proportion for post-bronchodilator FEV1 at weeks 12 and 52.
- 02Study Evidence
Tested in a randomized controlled trial (n = 938) at the randomized clinical trial stage.
- 03Practical Meaning
Controlled trial findings show causal benefit under protocol rules; real-world effectiveness can vary across patients.
Biological Mechanism & Study Design
Study Design & Cohort
Randomized controlled trial
Randomized controlled trial (n = 938) · Randomized Clinical Trial
Biological Pathway & Modality
Inflammation
Intervention: Dupilumab is associated with improved lung functions in patients with COPD and type
Experimental Findings & Endpoints
To perform in-depth analyses of the efficacy of dupilumab on lung function parameters in patients with COPD and type 2 inflammation.
In BOREAS (NCT03930732) and NOTUS (NCT04456673), patients with COPD and type 2 inflammation were randomized to dupilumab 300 mg (n = 938) or placebo (n = 936) subcutaneously every 2 weeks for 52 weeks. Dupilumab versus placebo improved pre-bronchodilator forced expiratory volume in 1 second (FEV1; least squares mean difference: 83 [a clinically meaningful level confidence interval (CI): 53-112] mL; P <.0001), post-bronchodilator FEV1 (71 [41-101] mL; P <.0001), pre-bronchodilator forced vital capacity (FVC; 64 [26-102] mL; P =.0009), post-bronchodilator FVC (41 [3-79] mL; P =.0341), post-bronchodilator FEV1/FVC (0.016 [0.010-0.022]; P <.0001), and forced expiratory flow a clinically meaningful level-a clinically meaningful level of FVC (78 [45-111] mL/s; P <.0001) at week 12 and sustained to week 52.
Improvements in pre-bronchodilator FEV1 were observed regardless of smoking status or the presence of co-existing emphysema; greater improvements were observed in patients with higher baseline eosinophil counts or fractional exhaled nitric oxide. Dupilumab versus placebo achieved >100 mL improvements in pre-bronchodilator FEV1 at week 12 (a clinically meaningful level vs a clinically meaningful level) and week 52 (a clinically meaningful level vs a clinically meaningful level), with a similar proportion for post-bronchodilator FEV1 at weeks 12 and 52.
Clinical Translation & Practice Context
Dupilumab treatment resulted in early and sustained improvements across multiple spirometric lung function parameters in patients with COPD and type 2 inflammation.
The Bottom Line · Clinical Pearl
“Dupilumab treatment resulted in early and sustained improvements across multiple spirometric lung function parameters in patients with COPD and type 2 inflammation.”
Published in American Journal of Respiratory and Critical Care Medicine · Current Stage: Randomized Clinical Trial